Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers

Patent metadata

Field	Value
Publication number	US-9835572-B2
Application number	US-201615016529-A
Country	US
Kind code	B2
Filing date	Feb 5, 2016
Priority date	Dec 15, 2009
Publication date	Dec 5, 2017
Grant date	Dec 5, 2017

Abstract

The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.

First claim

The invention claimed is:

1. A method for identifying therapeutic polymeric nanoparticle compositions with a desired therapeutic agent release rate profile, comprising:
a) providing a first aqueous suspension of at least one first plurality of polymeric nanoparticles each comprising a therapeutic agent, a block copolymer having at least one hydrophobic portion and at least one hydrophilic portion, wherein the therapeutic agent is selected from the group consisting of taxane agents, vinca alkaloids, nitrogen mustard agents, mTOR inhibitors, boronate esters; and peptide boronic acid compounds;
b) determining the nanoparticle glass transition temperature for the first aqueous suspension;
c) varying the amount or molecular weight of the hydrophobic portion of the block copolymer to provide a second aqueous suspension comprising a plurality of polymeric nanoparticles each comprising the therapeutic agent, if the glass transition temperature of step b) is below 37° C.; and
d) repeating steps b) and c) until an aqueous suspension with a glass transition temperature of between about 37° C. and about 50° C. and the desired therapeutic agent release rate profile is obtained.

2. The method of claim 1 , wherein the method further comprises: e) confirming the determined drug release rate from the second aqueous suspension using an in vitro dissolution test.

3. The method of claim 1 , wherein the therapeutic agent is a taxane agent.

4. The method of claim 3 , wherein the taxane agent is docetaxel.

5. The method of claim 1 , wherein the hydrophobic portions of the block copolymer is selected from poly(D,L-lactic) acid and poly(lactic acid-co-glycolic acid), and the hydrophilic portion is poly(ethylene)glycol.

6. The method of claim 5 , wherein the polymeric nanoparticle comprises about 0.2 to about 35 weight percent of the therapeutic agent; about 10 to about 99 weight percent poly(D,L-lactic) acid-block-poly(ethylene)glycol copolymer or poly(lactic)-co-poly(glycolic) acid-block-poly(ethylene)glycol copolymer; and about 0 to about 50 weight percent poly(D,L-lactic) acid or poly(lactic) acid-co-poly(glycolic) acid.

7. The method of claim 6 , wherein the poly(D,L-lactic) acid portion of the block copolymer has a weight average molecular weight of about 16 kDa, and the poly(ethylene)glycol portion of the first block copolymer has a weight average molecular weight of about 5 kDa.

8. The method of claim 1 , wherein the desired drug release rate of the therapeutic agent from the therapeutic polymeric nanoparticle composition is less than about 50% as determined in an in vitro dissolution test at a 4 hour time point.

9. The method of claim 1 , wherein the desired drug release rate of the therapeutic agent from the therapeutic polymeric nanoparticle composition is between about 70 to about 100% as determined in an in vitro dissolution test at a 4 hour time point.

10. The method of claim 1 , wherein the glass transition temperature is determined by modulated differential scanning calorimetry.

11. The method of claim 1 , wherein the glass transition temperature is determined by differential scanning calorimetry.

12. The method of claim 2 , wherein the in vitro dissolution test comprises suspension and centrifuge.

13. The method of claim 1 , wherein the therapeutic agent is selected from the group consisting of vinca alkaloids, nitrogen mustard agents, mTOR inhibitors, boronate esters, and peptide boronic acid compounds.

14. A method for screening nanoparticle suspensions to identify a suspension having a specific release rate, comprising:
a) separately preparing a plurality of suspensions each suspension having nanoparticles comprising a therapeutic agent, a block copolymer having at least one hydrophobic portion and at least one hydrophilic portion, and optionally a homopolymer selected from poly(D,L-lactic) acid or poly(lactic) acid-co-poly(glycolic) acid; wherein each suspension is in a separate compartment, and each suspension comprises a pre-determined molecular weight of the block copolymer and if present, a pre-determined molecular weight of the homopolymer; and wherein the therapeutic agent is selected from the group consisting of taxane agents, vinca alkaloids, nitrogen mustard agents, mTOR inhibitors, boronate esters; and peptide boronic acid compounds;
b) determining the nanoparticle glass transition temperature of each of the suspensions; and
c) identifying the suspension having a pre-determined glass transition temperature thereby identifying the suspension with the specific release rate, wherein the pre-determined glass transition temperature is between about 37° C. and about 50° C.

Assignees

• Pfizer

Inventors

• Zale Stephen E
• Troiano Greg
• Ali Mir M
• Hrkach Jeff
• Wright James

Classifications

• A61P5/38

  of the suprarenal hormones · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title